Current treatment considerations in metastatic renal cell carcinoma.
about
In silico design and biological evaluation of a dual specificity kinase inhibitor targeting cell cycle progression and angiogenesisBreathing new life into immunotherapy: review of melanoma, lung and kidney cancerThe current status of tailor-made medicine with molecular biomarkers for patients with clear cell renal cell carcinoma.Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.Tivozanib in the treatment of renal cell carcinoma.Targeting interleukins to treat severe asthma.Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma.Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR.CAR T cells: driving the road from the laboratory to the clinic.Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Periostin promotes migration and invasion of renal cell carcinoma through the integrin/focal adhesion kinase/c-Jun N-terminal kinase pathway.The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma.Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.Neuronal pentraxin 2 supports clear cell renal cell carcinoma by activating the AMPA-selective glutamate receptor-4Differential expression of microRNA501-5p affects the aggressiveness of clear cell renal carcinoma.Effect of the cytokine levels in serum on osteosarcoma.The Role of YB1 in Renal Cell Carcinoma Cell Adhesion
P2860
Q28544931-651F7386-8A0B-4C2C-990E-946D1D62AA4EQ33862861-84EB31BD-ACF6-4238-98AF-3DDB275C3A59Q34365135-6336E5EF-2786-43CA-9B0D-BB44CD3AA9A7Q36818377-C3061793-A1B6-4E06-8969-E0CB80E43E18Q36933605-1C71C55A-F0C3-4349-8AAC-AFE1D158E723Q38042721-2929ED22-39CC-4ECC-BFE5-FC0881189D3BQ38063500-39FA5595-C43A-4468-A5F2-A73544C82C2CQ38068584-9590ABD1-ECAD-463F-8C92-E076C160A48DQ38170499-B5D4C8D0-DD21-4CDC-834B-846AB9631776Q38248440-F13E853A-B6D8-47AC-AB9E-363178F1277BQ38708744-9F707111-5D2D-485E-ABBF-648463D4AE8DQ38825250-50D077CA-D76F-4737-B9D7-B0ED618030F6Q38979602-DCBE3B96-70AA-429C-BE3B-4D7DD395259BQ38981597-D3560017-82E1-4CD7-858D-61E971ADC710Q41966602-12831244-3393-490D-9391-C1D17B122379Q44602075-87DD2AFA-4BB3-4941-95F5-0EC1406D33DFQ57135008-B1CCB6FB-CBDB-4ECF-9D33-3F3404E5CD67
P2860
Current treatment considerations in metastatic renal cell carcinoma.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Current treatment considerations in metastatic renal cell carcinoma.
@en
Current treatment considerations in metastatic renal cell carcinoma.
@nl
type
label
Current treatment considerations in metastatic renal cell carcinoma.
@en
Current treatment considerations in metastatic renal cell carcinoma.
@nl
prefLabel
Current treatment considerations in metastatic renal cell carcinoma.
@en
Current treatment considerations in metastatic renal cell carcinoma.
@nl
P2860
P1476
Current treatment considerations in metastatic renal cell carcinoma.
@en
P2093
Brian I Rini
Housam Haddad
P2860
P2888
P304
P356
10.1007/S11864-012-0182-8
P577
2012-06-01T00:00:00Z